Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619495 · ClinicalTrials.gov registry record
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 120,000
- Enrollment target
NCT07619495: Completed study, sponsored by Brigham and Women's Hospital.
NCT07619495 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 120,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619495 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 120,000 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
To evaluate the comparative effect of injectable semaglutide vs dulaglutide on the composite of all-cause mortality, myocardial infarction, or stroke in patients typically treated in clinical practice who are at low, moderate, and high cardiovascular risk with type 2 diabetes and overweight.
Interventions
- DRUG Semaglutide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120,000 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2026-06-01 |
What the finished NCT07619495 record still lists
NCT07619495 is an observational study that tracks outcomes without assigning an intervention. Its 120,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT07619495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07619495 about?
NCT07619495 is a clinical study titled "Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07619495?
This trial is currently completed. The enrollment target is 120,000 participants. The study started on 2026-01-20. Estimated completion is 2026-06-01.
What interventions are being tested in trial NCT07619495?
The interventions under investigation include: Semaglutide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07619495?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- NCT06251323 · 119,680 participants · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI